UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 9, 2017

 

 

BioCrude Technologies USA, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada 000-55818 81-2924160
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number)

 

 

1255 Phillips Square, Suite 605

Montreal, QB, Canada H3B 3G5

(Address of Principal Executive Offices) (Zip Code)

 

514-962-0070

(registrant's telephone number, including area code)

 

Not Applicable

(former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to

simultaneously satisfy the filing obligation of the registrant under any of the

following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

ITEM 4.01. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

 

(1)PREVIOUS INDEPENDENT AUDITORS:

 

a.On August 7, 2017, the Company terminated GBH CPAs, PC, (“GBH”) as its registered independent public accountant.

 

b.GBH’s report on the financial statements for the years ended December 31, 2015 and 2016, and for the period August 4, 2015 (date of inception) through December 31, 2016 contained no adverse opinion or disclaimer of opinion and was not qualified or modified as to audit scope or accounting, except that the report contained an explanatory paragraph stating that there was substantial doubt about the Company's ability to continue as a going concern.

 

c.Our Board of Directors participated in and approved the decision to change independent accountants. Through the period covered by the financial audit for the years ended December 31, 2016 there have been no disagreements with GBH on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements if not resolved to the satisfaction of GBH would have caused them to make reference thereto in their report on the financial statements. Through the interim period August 7, 2017 (the date of termination of the former accountant), there have been no disagreements with GBH on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements if not resolved to the satisfaction of GBH would have caused them to make reference thereto in their report on the financial statements.

 

d.We have authorized GBH to respond fully to the inquiries of the successor accountant.

 

e.During the years ended December 31, 2015 and 2016 and the interim period through August 7, 2017, there have been no reportable events with us as set forth in Item 304(a)(1)(iv) of Regulation S-K.

 

f.The Company provided a copy of the foregoing disclosures to GBH prior to the date of the filing of this Report and requested that GBH furnish it with a letter addressed to the Securities & Exchange Commission stating whether or not it agrees with the statements in this Report. A copy of such letter has not yet been received but will be filed as Exhibit 16.1 to an amendment to this Form 8-K upon reciept.

 

(2)NEW INDEPENDENT ACCOUNTANTS:

 

a.On August 21, 2017, the Company engaged DALE MATHESON CARR-HILTON

LABONTE LLP, CHARTERED PROFESSIONAL ACCOUNTANTS ("DMCHL") of Vancouver, BC as its new registered independent public accountant. During the years ended December 31, 2015 and 2016 and prior to August 21, 2017 (the date of the new engagement), we did not consult with DMCHL regarding (i) the application of accounting principles to a specified transaction, (ii) the type of audit opinion that might be rendered on the Company's financial statements by DMCHL, in either case where written or oral advice provided by DMCHL would be an important factor considered by us in reaching a decision as to any accounting, auditing or financial reporting issues or (iii) any other matter that was the subject of a disagreement between us and our former auditor or was a reportable event (as described in Items 304(a)(1)(iv) or Item 304(a)(1)(v) of Regulation S-K, respectively).

 
 

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

 

a.None.
b.Exhibits

 

 

Number Exhibit
16.1 None.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BIOCRUDE TECHNOLOGIES USA, INC.

 

 

 

Dated: August 22, 2017

/s/ John Moukas

John Moukas

Chief Executive Officer